H.C. Wainwright Reaffirms Their Buy Rating on IMV Inc. (IMV)

By Jason Carr

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on IMV Inc. (IMVResearch Report), with a price target of $11.50. The company’s shares closed last Monday at $2.63, close to its 52-week low of $2.25.

According to TipRanks.com, Pantginis has currently no stars on a ranking scale of 0-5 stars, with an average return of -12.8% and a 29.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Inc., Applied Genetic Technologies, and Iovance Biotherapeutics Inc.

IMV Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $11.25.

See today’s analyst top recommended stocks >>

Based on IMV Inc.’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $3.78 million. In comparison, last year the company had a GAAP net loss of $4.58 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

IMV, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm’s patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system.